339 related articles for article (PubMed ID: 28578209)
1. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
2. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
Beall RF; Kuhn R; Attaran A
Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
[TBL] [Abstract][Full Text] [Related]
3. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
Hoen E'; Berger J; Calmy A; Moon S
J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
[TBL] [Abstract][Full Text] [Related]
4. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
Chien CV
PLoS One; 2007 Mar; 2(3):e278. PubMed ID: 17372625
[TBL] [Abstract][Full Text] [Related]
5. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
[TBL] [Abstract][Full Text] [Related]
6. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
[TBL] [Abstract][Full Text] [Related]
7. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
[TBL] [Abstract][Full Text] [Related]
8. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
9. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
't Hoen EFM; Kujinga T; Boulet P
J Pharm Policy Pract; 2018; 11():31. PubMed ID: 30524732
[TBL] [Abstract][Full Text] [Related]
10. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
11. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
12. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
McGIVERN L
Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
[TBL] [Abstract][Full Text] [Related]
13. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
14. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
Jain D; Darrow JJ
Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
[TBL] [Abstract][Full Text] [Related]
15. In which developing countries are patents on essential medicines being filed?
Beall RF; Blanchet R; Attaran A
Global Health; 2017 Jun; 13(1):38. PubMed ID: 28651631
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing global antiretroviral procurement prices.
Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
[TBL] [Abstract][Full Text] [Related]
17. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
18. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
[TBL] [Abstract][Full Text] [Related]
19. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
[TBL] [Abstract][Full Text] [Related]
20. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
Crager SE; Guillen E; Price M
Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
